文献速递心脑血管急症重症综合管理与镇静镇痛

金刚烷胺与莫达非尼作为急性卒中后的神经兴奋剂:重症监护室患者的回顾性研究

Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients.
PubMed 文献 · Neurocrit Care · 2021-01-01
一句话结论急性卒中ICU患者使用金刚烷胺和/或莫达非尼可能改善觉醒,53%在9天内达到应答标准,但需前瞻性对照研究确认。

该回顾性研究纳入87例急性非创伤性缺血性卒中、脑出血或蛛网膜下腔出血的成人ICU患者,描述金刚烷胺和/或莫达非尼的用药实践并评估安全性和有效性。神经兴奋剂在中位卒中后7天启动,最常见起始剂量为金刚烷胺100 mg每日两次(86%)和莫达非尼100 mg每日两次(54%)。可评估的79例中42例(53%)在启动后9天内达到应答标准,应答者出院回家或转急性康复的比例高于无应答者(90% vs 62%,p=0.006)。最常见潜在不良反应为睡眠紊乱(16%)。作者认为神经兴奋剂可能改善觉醒,但需前瞻性对照研究确认。

要点

  • 87例急性卒中ICU患者中,金刚烷胺初始使用71例(82%),莫达非尼13例(15%),两者联用3例(3%)。
  • 神经兴奋剂启动中位时间为卒中后7天(范围1-27天),最常见起始剂量为金刚烷胺100 mg每日两次(86%)和莫达非尼100 mg每日两次(54%)。
  • 可评估的79例中42例(53%)在启动后9天内达到应答标准,中位应答时间为3天(范围2-5天)。
  • 应答者出院回家或转急性康复的比例高于无应答者(90% vs 62%,p=0.006)。
  • 最常见潜在不良反应为睡眠紊乱(16%);幸存者中63/72(88%)出院时继续处方神经兴奋剂。

适用人群与场景

  • 连续成人ICU患者,因急性非创伤性缺血性卒中、脑出血或蛛网膜下腔出血接受金刚烷胺和/或莫达非尼治疗。

诊断标准与关键阈值

  • 应答标准:在神经兴奋剂启动后9天内满足以下三项中的两项:GCS评分较治疗前基线增加≥3分;护理记录中记录的觉醒或参与改善;物理治疗或职业治疗记录中记录的临床改善。

处置流程与药物剂量

  • 金刚烷胺最常见起始剂量为100 mg每日两次(86%的患者);莫达非尼最常见起始剂量为100 mg每日两次(54%的患者)。
  • 神经兴奋剂启动中位时间为卒中后7天(四分位距4.25-12.75天,范围1-27天),启动原因包括嗜睡(77%)、不遵嘱(32%)、无睁眼(28%)或低GCS(17%)。

研究设计与关键结果

  • 回顾性研究纳入87例可评估患者,其中脑出血41例(47%)、缺血性卒中29例(33%)、蛛网膜下腔出血17例(20%)。
  • 初始神经兴奋剂为金刚烷胺71例(82%)、莫达非尼13例(15%)、两者联用3例(3%)。
  • 有效性评估纳入79例,42例(53%)为应答者;金刚烷胺单药治疗者中34/62(55%)为应答者,金刚烷胺与莫达非尼联用者中8/24(33%)为应答者;莫达非尼单药治疗者中无应答者。
  • 从启动到应答的中位时间为3天(范围2-5天);应答者出院回家或转急性康复的比例高于无应答者(90% vs 62%,p=0.006)。
  • 幸存者中63/72(88%)出院时处方神经兴奋剂;最常见潜在不良反应为睡眠紊乱(16%)。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为神经兴奋剂给药可能改善急性卒中后的觉醒。
  • 作者建议未来需要采用神经兴奋剂给药方案、前瞻性评估以及明确界定的应答和安全标准的对照研究来确认这些令人鼓舞的发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: Neurostimulants may improve or accelerate cognitive and functional recovery after intracerebral hemorrhage (ICH), ischemic stroke (IS), or subarachnoid hemorrhage (SAH), but few studies have described their safety and effectiveness in the intensive care unit (ICU). The objective of this study was to describe amantadine and modafinil administration practices during acute stroke care starting in the ICU and to evaluate safety and effectiveness.

METHODS: Consecutive adult ICU patients treated with amantadine and/or modafinil following acute non-traumatic IS, ICH, or SAH were evaluated. Neurostimulant administration data were extracted from the electronic medication administration record, including medication (amantadine, modafinil, or both), starting dose, time from stroke to initiation, and whether the neurostimulant was continued at hospital discharge. Patients were considered responders if they met two of three criteria within 9 days of neurostimulant initiation: increase in Glasgow coma scale (GCS) score ≥ 3 points from pre-treatment baseline, improved wakefulness or participation documented in caregiver notes, or clinical improvement documented in physical or occupational therapy notes. Potential confounders of the effectiveness assessment and adverse drug effects were also recorded.

RESULTS: A total of 87 patients were evaluable during the 3.7-year study period, including 41 (47%) with ICH, 29 (33%) with IS, and 17 (20%) with SAH. The initial neurostimulant administered was amantadine in 71 (82%) patients, modafinil in 13 (15%), or both in 3 (3%) patients. Neurostimulants were initiated a median of 7 (4.25, 12.75) days post-stroke (range 1-27 days) for somnolence (77%), not following commands (32%), lack of eye opening (28%), or low GCS (17%). The most common starting dose was 100 mg twice daily for both amantadine (86%) and modafinil (54%). Of the 79 patients included in the effectiveness evaluation, 42 (53%) were considered responders, including 34/62 (55%) receiving amantadine monotherapy and 8/24 (33%) receiving both amantadine and modafinil at the time they met the definition of a responder. No patient receiving modafinil monotherapy was considered a responder. The median time from initiation to response was 3 (2, 5) days. Responders were more frequently discharged home or to acute rehabilitation compared to non-responders (90% vs 62%, p = 0.006). Among survivors, 63/72 (88%) were prescribed a neurostimulant at hospital discharge. The most common potential adverse drug effect was sleep disruption (16%).

CONCLUSIONS: Neurostimulant administration during acute stroke care may improve wakefulness. Future controlled studies with a neurostimulant administration protocol, prospective evaluation, and discretely defined response and safety criteria are needed to confirm these encouraging findings.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Leclerc AM, Riker RR, Brown CS, et al. Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients. Neurocrit Care. 2021. PMID: 32435964. doi:10.1007/s12028-020-00986-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。